Mirador Therapeutics develops precision medicines for immune-mediated diseases.
Mirador Therapeutics has raised $250.0M in total funding. The most recent round was Series B. The last funding was announced in January 2026.
Mirador Therapeutics's investors include Blue Owl, ARCH Venture Partners, Sanofi, RTW Investments, Fidelity.
Mirador Therapeutics is headquartered in San Diego, United States.
Mirador Therapeutics develops precision medicines for immune-mediated diseases.
Mirador Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mirador Therapeutics — Funding & Investors." VCBacked, January 12, 2026, https://www.vcbacked.co/company/mirador-therapeutics. Accessed September 15, 2026.
VCBacked. (2026). Mirador Therapeutics — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/mirador-therapeutics
{{cite web |title=Mirador Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/mirador-therapeutics |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated